Age modifies recurrence risk across the 2025 American Thyroid Association risk stratification in papillary thyroid carcinoma
Open Access
- 2 November 2026
- journal article
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (12)
Abstract
Context: The 2025 American Thyroid Association (ATA) guidelines updated recurrence risk stratification for papillary thyroid cancer (PTC). Whether age modifies the absolute structural recurrence risk represented by these strata is unclear. Objective: To determine whether age modifies 5-year structural recurrence risk across ATA 2025 stratification in PTC and improves risk prediction. Methods: This retrospective cohort study included 14 397 patients with PTC who underwent initial surgery at a tertiary cancer center in China from 2000 to 2018. The primary outcome was 5-year structural recurrence-free survival. Cox models with restricted cubic splines evaluated age effects and ATA2025-by-age interaction. ATA-based and age-interaction models were compared by temporal validation and decision-curve analysis. Results: The median age was 43.0 years, 10 867 patients (75.5%) were female, and 758 (5.3%) experienced structural recurrence during a median follow-up of 60.0 months. Observed 5-year risk rose from 1.7% to 12.5% across ATA2025 stratification. Age modified risk across stratifications (global interaction P < .001). After treatment adjustment, 5-year risk fell from 2.37% at age 35 years to 0.69% at age 65 years in the low-risk group but rose from 8.21% to 19.28% in the high-risk group. In temporal validation, the C-index was 0.745 for both models; 5-year areas under the curve were 0.743 and 0.747, and Brier scores were 0.043 and 0.042. Decision curves showed little overall difference. Conclusion: Age identified meaningful heterogeneity in absolute structural recurrence risk, particularly in high-risk PTC, but added little to predictive performance or decision value. External validation is required before age is used to guide treatment or surveillance.Funding Information
- National High Level Hospital Clinical Research (2025-LYZX-Z-A08)
- National Natural Science Foundation of China (222783492278349)
This publication has 13 references indexed in Scilit:
- 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid CancerThyroid®, 2025
- Multicenter Retrospective Analysis of Pediatric Differentiated Thyroid Carcinoma: Treatment Practices and Outcomes Prior to Pediatric American Thyroid Association Guidelines ImplementationPediatric Blood & Cancer, 2025
- The U-shaped association between age at diagnosis and recurrence in patients with papillary thyroid carcinoma: A retrospective single-institution cohort studyEuropean Journal of Surgical Oncology, 2024
- Age Stratification and Prognostic Factor Analysis in Pediatric Differentiated Thyroid CancerThe Laryngoscope, 2024
- Prognostic Factors Improving ATA Risk System and Dynamic Risk Stratification in Low- and Intermediate-Risk DTC PatientsThe Journal of Clinical Endocrinology & Metabolism, 2023
- Thyroid cancerThe Lancet, 2023
- Patient Age Is an Independent Risk Factor of Relapse of Differentiated Thyroid Carcinoma and Improves the Performance of the American Thyroid Association Stratification SystemThyroid®, 2020
- Using the American Thyroid Association Risk-Stratification System to Refine and Individualize the American Joint Committee on Cancer Eighth Edition Disease-Specific Survival Estimates in Differentiated Thyroid CancerThyroid®, 2018
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2016
- Patient Age Is Significantly Related to the Progression of Papillary Microcarcinoma of the Thyroid Under ObservationThyroid®, 2014